Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 4/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254807 | 1.00 | KDM4E (0.38) | KDM4EKMT2ASMN1; SMN2ESR1MET | |
| SCHEMBL13408171 | 0.83 | RAB9A (0.44) | KDM4EKMT2ASMN1; SMN2LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL1253471 | 0.82 | RAB9A (0.43) | KDM4EKMT2ASMN1; SMN2LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL1253468 | 0.82 | RAB9A (0.43) | KDM4EKMT2ASMN1; SMN2LMNACYP3A4 | |
| SCHEMBL24661853 | 0.76 | APP (0.39) | KDM4EKMT2ASMN1; SMN2ESR1NR1H4 | |
| SCHEMBL1768856 | 0.75 | MET (0.47) | KDM4EKMT2ASMN1; SMN2ESR1MET | |
| SCHEMBL7936748 | 0.75 | MET (0.47) | KDM4EKMT2ASMN1; SMN2ESR1MET | |
| SCHEMBL1254169 | 0.75 | ACHE (0.35) | KDM4EKMT2ASMN1; SMN2NR1H4 | |
| SCHEMBL1254170 | 0.75 | ACHE (0.35) | KDM4EKMT2ASMN1; SMN2NR1H4 | |
| SCHEMBL24661856 | 0.74 | APP (0.37) | KDM4EKMT2ASMN1; SMN2ESR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848614-A2 | Acrylamide derivatives as antibiotic agents | Debiopharm International SA (CH) | 2015-03-18 | — | — | EP | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8450307-B2 | Therapeutic agents, and methods of making and using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | KDM4E 4494/4885KMT2A 4314/4885SMN1; SMN2 1952/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | KDM4E 4139/4885KMT2A 4353/4885SMN1; SMN2 4007/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | KDM4E 4494/4885KMT2A 4314/4885SMN1; SMN2 1952/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | KDM4E 4139/4885KMT2A 4353/4885SMN1; SMN2 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.